Compare KPTI & ACNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | ACNT |
|---|---|---|
| Founded | 2008 | 1945 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.0M | 154.0M |
| IPO Year | 2013 | N/A |
| Metric | KPTI | ACNT |
|---|---|---|
| Price | $6.71 | $16.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $22.17 | N/A |
| AVG Volume (30 Days) | ★ 424.7K | 46.9K |
| Earning Date | 02-18-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | $142,530,000.00 | ★ $171,413,000.00 |
| Revenue This Year | $3.82 | $22.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $172.87 |
| Revenue Growth | N/A | ★ 65.05 |
| 52 Week Low | $3.51 | $10.85 |
| 52 Week High | $10.75 | $16.89 |
| Indicator | KPTI | ACNT |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 48.99 |
| Support Level | $5.88 | $15.76 |
| Resistance Level | $7.09 | $16.67 |
| Average True Range (ATR) | 0.69 | 0.36 |
| MACD | -0.16 | -0.12 |
| Stochastic Oscillator | 30.08 | 18.22 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Ascent Industries Co is a specialty chemicals platform focused on the development, production, and distribution of tailored, performance-driven chemical solutions. It has one reportable segment: Specialty Chemicals. The Specialty Chemicals segment includes the operating results of the Company's plants involved in the production of specialty chemicals and produces critical ingredients and process aids for the oil & gas, household, industrial and institutional (HII), personal care, coatings, adhesives, sealants and elastomers (CASE), pulp and paper, textile, automotive, agricultural, water treatment, construction and other industries.